SCHEMBL2740993

SCHEMBL2740993

O=[N+]([O-])c1ccc(N/N=C/c2ccnc3ccccc23)c(S(=O)(=O)Nc2ccccc2Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.55
▸ MEN1 O00255 12/20 0.55
▸ KMT2A Q03164 12/20 0.55
▸ GAA P10253 8/20 0.55
▸ HTT P42858 7/20 0.55
▸ NPSR1 Q6W5P4 3/20 0.55
▸ ALDH1A1 P00352 5/20 0.53
▸ GLA P06280 1/20 0.53
▸ TLR9 Q9NR96 1/20 0.53
▸ RAB9A P51151 7/20 0.52
▸ SMN1; SMN2 Q16637 6/20 0.52
▸ NPC1 O15118 6/20 0.52
▸ PSMD14 O00487 2/20 0.52
▸ PIK3CA P42336 1/20 0.51
▸ PLA2G1B P04054 1/20 0.50
▸ ATG4B Q9Y4P1 1/20 0.50
▸ XBP1 P17861 1/20 0.50
▸ TNNI3 P19429 1/20 0.49
▸ TNNT2 P45379 1/20 0.49
▸ TNNC1 P63316 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13128956 0.86 MEN1 (0.48) MAPTMEN1KMT2AGAAHTT
SCHEMBL2740987 0.83 MEN1 (0.55) MAPTMEN1KMT2AGAAHTT
SCHEMBL2740986 0.82 MEN1 (0.56) MAPTMEN1KMT2AGAAHTT
SCHEMBL2741013 0.80 MEN1 (0.58) MAPTMEN1KMT2AGAAHTT
SCHEMBL2741006 0.80 MEN1 (0.55) MAPTMEN1KMT2AGAAHTT
SCHEMBL2740951 0.80 MEN1 (0.57) MAPTMEN1KMT2AGAAHTT
SCHEMBL2740985 0.80 MEN1 (0.54) MAPTMEN1KMT2AGAAHTT
SCHEMBL2740949 0.79 MEN1 (0.54) MAPTMEN1KMT2AGAAHTT
SCHEMBL2740948 0.78 L3MBTL1 (0.55) MAPTMEN1KMT2AGAAHTT
SCHEMBL2740990 0.78 L3MBTL1 (0.57) MAPTMEN1KMT2AGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 MAPT 4202/4885MEN1 1381/4885KMT2A 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback